Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 5/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.48 |
| ▸ | FBP1 | P09467 | 4/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346446 | 0.82 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBFBP1 | |
| SCHEMBL5358044 | 0.73 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBFBP1 | |
| SCHEMBL8333636 | 0.65 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBFBP1 | |
| SCHEMBL15304560 | 0.65 | CYP1A2 (0.47) | NPC1MAPT | |
| SCHEMBL2464198 | 0.64 | PIN1 (0.49) | NPC1MAPT | |
| SCHEMBL5369934 | 0.64 | FBP1 (1.00) | FBP1 | |
| SCHEMBL5358359 | 0.62 | ALDH1A1 (0.46) | PI4KAPI4K2BPI4K2API4KBFBP1 | |
| SCHEMBL2464197 | 0.61 | RAB9A (0.50) | NPC1MAPT | |
| SCHEMBL28367074 | 0.61 | TSHR (0.51) | NPC1MAPT | |
| SCHEMBL28362740 | 0.60 | TSHR (0.54) | NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
| US-6967193-B1 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6284748-B1 | ANTIDIABETIC AGENT | METABASIS THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
| WO-1998039344-A9 | NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039344-A1 | NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | PI4KA 1738/4885PI4K2B 1456/4885PI4K2A 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.